Clinical, Laboratory and Radiographic Features of Patients with Pneumonia and Parapneumonic Effusions
DOI:
https://doi.org/10.3889/oamjms.2016.091Keywords:
community-acquired pneumonia (CAP), parapneumonic effusion, empiema, clinical features, laboratory features, radiographic featuresAbstract
BACKGROUND: Parapneumonic effusions complicating pneumonia are associated with increased morbidity and mortality.
AIM: To determine the role of the clinical, laboratory and radiographic features to the differential diagnosis of patients with community- acquired pneumonia (CAP) without effusion, uncomplicated parapneumonic effusion (UCPPE) and complicated parapneumonic effusion (CPPE).
MATERIAL AND METHODS: We analysed 148 patients with CAP without effusion, 50 with UCPPE and 44 with CPPE. In three groups of patients, the majority was male patients (58.11%, 58%, 61.36%) consequently.
RESULTS: The chronic heart failure was the most common comorbidity in a group with CAP (28; 18.92%) and UCPPE (7; 14%), alcoholism (12;12.77%) in a group with CPPE. Patients with CPPE had significantly longer fever compared to patients with CAP without effusion (p = 0.003). Pleuritic chest pain (86.36%) and dyspnea (88.64%) were the most common symptoms in CPPE, then to group with UCPPE (60%; 52%), and in CAP without effusion (25.68%; 47,97%). Diffuse pulmonary changes were detected more frequently in the group with CAP without effusion compared with the group with CPPE (64.86 % vs. 27.27 %), while the segment lung changes were more common in patients with CPPE (50% vs. 20.27%). Patients with CPPE were significant with higher erythrocytes sedimentation rate (ESR), white blood cells (WBC) and serum C- reactive protein (CRP) than it the other two groups (p = 0.00090, p = 0.01, p= 0.000065).
CONCLUSION:Proper analysis of clinical, laboratory and radiographic features of patients with CAP and parapneumonic effusion can prevent mismanagement in these patients and will reduce morbidity and mortality.Â
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Light RW. Parapneumonic effusions and empiema. Proc Am Thorac Soc. 2006;3(1):75-80. http://dx.doi.org/10.1513/pats.200510-113JH PMid:16493154
Lim TK. Management of parapneumonic pleural effusion. Curr Opin In Pulm Med. 2001;7: 193-197. http://dx.doi.org/10.1097/00063198-200107000-00005
Finich S, Chalmers JD. Parapneumonic effusions: epidemiology and predictors of pleural infection. Curr Respir Care Rep. 2014;3:52-60. http://dx.doi.org/10.1007/s13665-014-0074-4
Mc Cauley L, Dean N. Pneumonia and empiema: causal, causal or unknown. J Thorac Dis. 2015;7(6):992-998.
Koegelenberg CFN, Diacon AH, Bolliger CT. Parapneumonic pleural effusin and empyema. Respiration. 2008;75:241-250. http://dx.doi.org/10.1159/000117172 PMid:18367849
Smith JA, Mulleroworth MH, Westlake GW, et al. Empyema thoracis: 14- year expirience in a teaching center. Ann Thorac Surg. 1991;51:39-42. http://dx.doi.org/10.1016/0003-4975(91)90443-T
Chapman SJ, Davies RJO. The management of pleural space infection. Respirology. 2004;9:4-11. http://dx.doi.org/10.1111/j.1440-1843.2003.00535.x PMid:14982595
Medford AR, Maskell N. Pleural effusion. Postgrad Med J. 2005;81:702e10.
Falk G, Fahey T. C-reactive protein and community-acquired pneumonia in ambulatory care: systematic review of diagnostic accuracy studies. Fam Pract. 2009;26(1):10-21. http://dx.doi.org/10.1093/fampra/cmn095 PMid:19074757
Chalmers JD, Singanayagam A, Murray MP, et al. Risk factors for complicated parapneumonic effusion and empyema on presentation to hospital with community-acquired pneumonia. Thorax. 2009;64(7):592-7. http://dx.doi.org/10.1136/thx.2008.105080 PMid:19131449
Falguera M, Carratalà J, Bielsa S, et al. Predictive factors, microbiology and outcome of patients with parapneumonic effusion. Eur Respir J. 2011; 38(5):1173-9. http://dx.doi.org/10.1183/09031936.00000211 PMid:21565916
Hasley PB, Albaum MN, Li Y-H, et al. Do pulmonary radiographic findings at presentation predict mortality in patients with community acquired pneumonia ? Arch Intern Med. 1996;156:2206- 2212. http://dx.doi.org/10.1001/archinte.1996.00440180068008 PMid:8885819
Metlay JP, Schulz R, li YH, et al. Influence of age on symptoms at presentation in patents with community- acquired pneumonia. Arch Intern Med. 1997;157:1453-9. http://dx.doi.org/10.1001/archinte.1997.00440340089009 PMid:9224224
Finich S, Chalmers JD. Brief clinical review: Non- responding pneumonia. EMJ Respir. 2014;104-111.
Huang H-C, Chang H-Y, Chen C-W, et al. Predicting factors for outcome of tube thoracostomy in complicated parapneumonic effusion or empiema. Chest. 1999;115:751-756. http://dx.doi.org/10.1378/chest.115.3.751
Tsang KY, Leung WS, Chan VL, et al. Complicated parapneumonic effusion and empiema thoracis: microbiology and predictors of adverse outcomes. Hong Kong Med J. 2007; 13:178-86. PMid:17548905
Sahn SA. Diagnosis and management of parapneumonic effusions and empyema. Clinical Infectious Diseases. 2007;45:1480-6. http://dx.doi.org/10.1086/522996 PMid:17990232
Rosenstengel A, Gary Lee YC. Pleural infection- current diagnosis and management J Thorac Dis. 2012;4(2):186-193. PMid:22833824 PMCid:PMC3378219
McGrath EE Anderson PB. Diagnosis of pleural effusion: A systematic approach. American Journal of Critical Care. 2011;20:119-128. http://dx.doi.org/10.4037/ajcc2011685 PMid:21362716
Chapman SJ, Davies RJO. The management of pleural space infection. Curr Opin Pulm Med. 2004;10:299-304. http://dx.doi.org/10.1097/01.mcp.0000129755.79467.67 PMid:15220756
Girdhar A, Shujaat A, Bajwa A. Management of infectious processes of the pleural space: a review. Pulmonary Medicine. 2012; 2012:816502. http://dx.doi.org/10.1155/2012/816502 PMid:22536502 PMCid:PMC3317076
Krüger S, Ewig S, Papassotiriou J, et al. Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP: results from the German competence network CAPNETZ. Respir Res. 2009;10:65. http://dx.doi.org/10.1186/1465-9921-10-65 PMid:19594893 PMCid:PMC2714042
Brigden ML. Clinical utility of the erythrocyte sedimentation rate. Am Fam Physician. 1999;60(5):1443-1450. PMid:10524488
Chalmers JD, Singanayagam A, Hill AT. C-reactive protein is an independent predictor of severity in community-acquired pneumonia. Am J Med. 2008;121(3):219-25. http://dx.doi.org/10.1016/j.amjmed.2007.10.033 PMid:18328306
Mira JP, Max A, Burgel PR. The role of biomarkers in community-acquired pneumonia: predicting mortality and response to adjunctive therapy. Crit Care. 2008;12(Suppl 6):S5. http://dx.doi.org/10.1186/cc7028 PMid:19105798 PMCid:PMC2607115
Eisenhut M. A persistently elevatd C- reactive protein level in pneumonia may indicate empiema. Critical Care. 2008;12:409. http://dx.doi.org/10.1186/cc6204 PMid:18341702 PMCid:PMC2374620
Tsai TH, Yang PC. Ultrasound in the diagnosis and management of pleural disease. Curr Opin Pulm Med. 2003;9(4):282-90. http://dx.doi.org/10.1097/00063198-200307000-00007
Yang PC, Luh KT, Chang DB, Wu HD, Yu CJ, Kuo SH. Value of sonography in determining the nature of pleural effusion: analysis of 320 cases. AJR Am J Roentgenol. 1992;159(1):29-33. http://dx.doi.org/10.2214/ajr.159.1.1609716 PMid:1609716
Downloads
Published
How to Cite
Issue
Section
License
http://creativecommons.org/licenses/by-nc/4.0